Health News Releases

  • Today February 19
July 23, 2015 15:55
Patient Safety Movement Foundation Announces the 4th Annual Patient Safety, Science & Technology Summit
The Patient Safety Movement Foundation (http://patientsafetymovement.org) announces the 4th annual Patient Safety, Science & Technology Summit (http://goo.gl/GVIFrr) on Jan. 22-23, 2016 at the Laguna
July 20, 2015 10:45
Patient Safety Movement Foundation’s Midyear Planning Meeting Co-convened with the Chapman University School of Pharmacy
The Patient Safety Movement Foundation (http://patientsafetymovement.org) is co-convening with Chapman University School of Pharmacy for their Midyear Planning Meeting on July 29, 2015 on Chapman’s ma
July 17, 2015 10:20
Efficacy Results of Otsuka’s Delamanid (Deltyba™) for Extensively Drug-Resistant Tuberculosis (XDR-TB) Published in the New England Journal of Medicine
Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced that data from a post-hoc subset analysis of its Phase IIb clinical trial suggesting potential efficacy of delamanid for the treatment of exten
July 16, 2015 11:00
Boehringer Ingelheim Welcomes the Inclusion of OFEV® (nintedanib*) in the Updated International Treatment Guidelines for Idiopathic Pulmonary Fibrosis (IPF)
Boehringer Ingelheim welcomes the international evidence-based 2015 ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis - An Update of the 2011 Guideline which sug
July 15, 2015 17:30
Takeda Submits New Drug Application for Ixazomib for Patients with Relapsed/Refractory Multiple Myeloma
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that a New Drug Application (NDA) has been submitted to the United States (U.S.) Food and Drug Administration (FDA) for ixazomib, an i
July 14, 2015 13:10
Masimo Renews its $1,000,000 Performance Guarantee that Masimo SET® Technology Will Outperform All Nellcor™ Pulse Oximeters
Masimo (NASDAQ: MASI), the inventor of measure-through motion and low perfusion pulse oximetry, today renewed its $1,000,000 (USD) performance guarantee that Masimo SET® Pulse Oximetry will outperform
July 07, 2015 09:15
Phase III data published in The Lancet Oncology shows a significant overall survival benefit of Giotrif® (afatinib) compared to Tarceva® (erlotinib)
Phase III data published in The Lancet Oncology shows a significant overall survival benefit of Giotrif® (afatinib) compared to Tarceva® (erlotinib) in patients with previously treated advanced squamo
July 03, 2015 11:45
Quintiles and Quest Diagnostics Launch Q2 Solutions
Quintiles (www.quintiles.com) and Quest Diagnostics (http://goo.gl/NbIXp) today announced the launch of Q2 Solutions (www.q2labsolutions.com), their new combined clinical trials laboratory services or
July 02, 2015 15:25
New advance in COPD maintenance treatment, Spiolto® Respimat®, approved in first European countries
Boehringer Ingelheim today announced regulatory authority approvals for Spiolto® Respimat® (tiotropium/olodaterol) in first European countries†. Spiolto® Respimat® is a once-daily maintenance treatmen
July 01, 2015 11:40
Turkey’s Leading University Hospital Adopts Masimo SpHb for Continuous Noninvasive Haemoglobin Monitoring
Masimo (www.masimo.co.uk) (NASDAQ: MASI) announced today that Turgut Ozal Medical Centre Liver Hospital (http://totm.inonu.edu.tr/index.php) in Malatya, Turkey, has installed Masimo’s noninvasive, con
June 30, 2015 14:00
Cranberry Juice May Help Protect Against Heart Disease and Diabetes Risk Factors
A new study[1] reveals that drinking low-calorie cranberry juice cocktail may help lower the risk of chronic diseases that rank among the leading causes of death worldwide, including heart disease, di
June 25, 2015 10:15
Estima Pharma Solutions LLP Wins CQE Award for Compliance on QC100 Total Quality Management Model Criteria for 2015
Recognized for Commitment to Quality, Excellence, Leadership, Technology and Innovation, Estima Pharma Solutions LLP, India, was presented the CQE Century International Quality ERA Award, for complian
June 25, 2015 02:00
Morinaga Milk Industry: Probiotic Supplementation Causes Fat Loss in Overweight Adults
Morinaga Milk Industry Co., Ltd. (TOKYO:2264), the second largest dairy product company in Japan, confirmed that its new probiotic ingredient, Bifidobacterium breve B-3, caused a significant reduction
June 24, 2015 10:40
Masimo Receives CE Mark for MightySat Rx Pulse Oximeter
Masimo (http://masimo.co.uk) (NASDAQ: MASI) today announced the CE Mark and full market release of MightySat™ Rx fingertip pulse oximeter for clinical use in CE countries, offering the same Masimo SET
June 23, 2015 10:10
Idarucizumab* reverses the anticoagulant effect of dabigatran within minutes in patient study
Results from an interim analysis of the Phase III RE-VERSE AD™ patient study demonstrate that 5 g of idarucizumab* immediately reversed the anticoagulant effect of dabigatran (Pradaxa®) in patients re
June 21, 2015 09:00
Dr. Seo Hyo-seok Gave Lecture on Unique Concepts of Korean Medicine at 2015 World Conference of Science Journalists
Dr. Seo Hyo-seok participated in the ‘2015 World Conference of Science Journalists’ held in COEX, Samsung-dong, Seoul, Korea from the 8th to the 12th in his capacity as a sponsor and explained the con
June 19, 2015 14:40
Gore Global Registry for Endovascular Aortic Treatment Enrolls 3,000 Patients
W. L. Gore & Associates, Inc. (www.goremedical.com) (Gore) announced that important updates from the Gore Global Registry for Endovascular Aortic Treatment (GREAT) will be presented today at the 2015
June 17, 2015 11:55
Cook Group President Kem Hawkins to Retire in July
Cook Group announced today that Kem Hawkins, president of Cook Group Incorporated, will retire on July 1 after 34 years with the Cook organization. Hawkins, who has been transitioning his role in the
June 16, 2015 17:20
New publication in The Lancet describes effective reversal of Pradaxa® in healthy volunteers
Today, The Lancet published results from a healthy volunteer study investigating the reversal of the anticoagulant effect of Pradaxa® (dabigatran etexilate) by its specific reversal agent idarucizumab
June 16, 2015 13:35
Quintiles Unveils New Predictive and Advanced Analytics Capabilities to Enhance its Risk-Based Monitoring Solution
Quintiles, the world’s largest biopharmaceutical services company, today announced the addition of advanced statistical monitoring and predictive analytics capabilities to its risk-based monitoring (R
June 11, 2015 11:45
Bioventus Leaders Promoted to Manage International Business and Expansion
Bioventus® (www.bioventusglobal.com), a leader in orthobiologic solutions, today announced promotions to its executive leadership team. Effective immediately Andrew Hosmer is promoted to Managing Dire
June 10, 2015 09:40
Oral Presentation Evaluating Pooled Data on OTEZLA® (apremilast) for Long-Term Improvements in Enthesitis and Dactylitis to Be Presented at EULAR
Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG), today announced that the findings from a long-term (104-week) post-hoc analysis of pooled data from the PALA
June 08, 2015 17:50
Type 2 diabetes: Patients reporting better quality of communication by their physician show improved self-care
New research shows that the quality of patient-physician communication, at the moment when additional oral type 2 diabetes (T2D) medication is prescribed (‘add-on’), is linked to future patient self-c
June 08, 2015 17:45
Type 2 diabetes: Empagliflozin/metformin demonstrates reductions in blood glucose in data presented at ADA
A Phase III clinical trial has found that empagliflozin in combination with metformin reduces blood glucose levels in adults with type 2 diabetes (T2D). Boehringer Ingelheim and Eli Lilly and Company
June 08, 2015 11:35
HOYA Group PENTAX Medical Launches Splash M-Knife, the New Multi-Functional ESD Device Contributing in Early Treatment of Gastric Cancer
HOYA Group PENTAX Medical launches Splash M-Knife, the new multi-functional ESD Device to achieve complete Endoscopic Submucosal Dissection (ESD herein after) with a single device. The new device will
25 per page50 per page75 per page100 per page